PMC:7534795 / 48345-48558
Annnotations
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T18 | 23-32 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T19 | 33-42 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T409 | 0-213 | Sentence | denotes | Moreover, about 14% of lopinavir–ritonavir recipients were unable to complete the full 14-day course of administration due primarily to the adverse events including the risks of QT prolongation (Cao et al., 2020). |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 33031856-32187464-84038893 | 207-211 | 32187464 | denotes | 2020 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1482 | 23-42 | Chemical | denotes | lopinavir–ritonavir | MESH:C558899 |
| 1498 | 178-193 | Disease | denotes | QT prolongation | MESH:D008133 |